The phase III IMpassion130 trial using chemotherapy plus atezolizumab (a fully humanized, engineered monoclonal antibody of IgG1 against the programmed cell death ligand 1, PD-L1) compared with chemotherapy plus placebo brought breast cancer into the era of antibody-based therapeutic approaches; however, limitations of the therapeutic antibody approach included high medical cost, poor tissue accessibility, insufficient pharmacokinetics, and imperfect interactions with the immune system. Here, CD274 is linked to breast cancer.